Focused On-demand Library for Interleukin-19

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries for receptors.

 Fig. 1. The sreening workflow of Receptor.AI

It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.







Alternative names:

Melanoma differentiation-associated protein-like protein; NG.1

Alternative UPACC:

Q9UHD0; B6VEV9; Q5VUT3; Q96QR4; Q9NUA0


Interleukin-19, known alternatively as Melanoma differentiation-associated protein-like protein or NG.1, plays a pivotal role in immune regulation. It functions as an anti-inflammatory and proangiogenic factor, influencing adaptive immunity towards an anti-inflammatory phenotype. This is achieved through the modulation of cytokines, including the down-regulation of IFN-gamma and up-regulation of IL4 and IL13. Produced by osteocytes, Interleukin-19 also promotes granulopoiesis and neutrophil formation. It exerts its effects via the IL20RA and IL20RB receptor complex, activating the JAK-STAT pathway, particularly STAT3.

Therapeutic significance:

Understanding the role of Interleukin-19 could open doors to potential therapeutic strategies, especially in conditions where modulation of the immune response is beneficial.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.